Literature DB >> 25139045

Cardiovascular disease risk is only elevated in hypertensive, formerly preeclamptic women.

N M Breetveld1, C Ghossein-Doha1, Smj van Kuijk2, A P van Dijk3, M J van der Vlugt3, W M Heidema4, R R Scholten4, M E A Spaanderman1.   

Abstract

OBJECTIVE: To analyse the predicted 10- and 30-year risk scores for cardiovascular disease (CVD) in patients who experienced preeclampsia (PE) 5-10 years previously compared with healthy parous controls.
DESIGN: Observational study.
SETTING: Tertiary referral hospital in the Netherlands. POPULATION: One hundred and fifteen patients with a history of PE and 50 controls. PE patients were categorised into two groups, hypertensive (n = 21) and normotensive (n = 94), based on use of antihypertensive medication, and next categorised into subgroups based on the onset of PE: early-onset PE (n = 39) and late-onset PE (n = 76).
METHODS: All participants underwent cardiovascular risk screening 5-10 years after index pregnancy. We measured body mass, height and blood pressure. Blood was analysed for fasting glucose, insulin and lipid levels. All participants completed a validated questionnaire. The 10- and 30-year Framingham risk scores were calculated and compared. MAIN OUTCOME MEASURES: Estimated Framingham 10- and 30-year risk scores for CVD.
RESULTS: The overall 10- and 30-year CVD median risks weighing subjects' lipids were comparable between formerly PE women and controls; 1.6 versus 1.5% (P = 0.22) and 9.0 versus 9.0% (P = 0.49), respectively. However, hypertensive formerly PE women have twice the CVD risk as normotensive formerly PE women: 10- and 30-year CVD median risks were 3.1 versus 1.5% (P < 0.01) and 19.0% versus 8.0% (P < 0.01), respectively. Risk estimates based on BMI rather than lipid profile show comparable results. Early-onset PE clustered more often in the hypertensive formerly PE group and showed significantly higher 10- and 30-year CVD risk estimates based on lipids compared with the late-onset PE group: 1.7 versus 1.3% (P < 0.05) and 10.0 versus 7.0% (P < 0.05), respectively.
CONCLUSIONS: Women who are hypertensive after preeclampsia, have a twofold risk of developing CVD in the next 10-30 years. Formerly PE women who are normotensive in the first 10 years after their preeclamptic pregnancy have a comparable future cardiovascular risk to healthy controls.
© 2014 Royal College of Obstetricians and Gynaecologists.

Entities:  

Keywords:  Cardiovascular risk; Framingham risk score; hypertension; metabolic syndrome; preeclampsia

Mesh:

Substances:

Year:  2014        PMID: 25139045     DOI: 10.1111/1471-0528.13057

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  15 in total

1.  Association of Pregnancy Complications and Characteristics With Future Risk of Elevated Blood Pressure: The Västerbotten Intervention Program.

Authors:  Nisha I Parikh; Margareta Norberg; Erik Ingelsson; Sven Cnattingius; Ramachandran S Vasan; Magnus Domellöf; Jan Håkan Jansson; Anna-Karin Edstedt Bonamy
Journal:  Hypertension       Date:  2017-01-30       Impact factor: 10.190

2.  Disparities in the Prevalence of Excess Heart Age Among Women with a Recent Live Birth.

Authors:  Jonetta Johnson Mpofu; Ruben A Smith; Deesha Patel; Cathleen Gillespie; Shanna Cox; Matthew Ritchey; Quanhe Yang; Brian Morrow; Wanda Barfield
Journal:  J Womens Health (Larchmt)       Date:  2019-08-08       Impact factor: 2.681

3.  Preeclampsia and cognitive impairment later in life.

Authors:  Julie A Fields; Vesna D Garovic; Michelle M Mielke; Kejal Kantarci; Muthuvel Jayachandran; Wendy M White; Alissa M Butts; Jonathan Graff-Radford; Brian D Lahr; Kent R Bailey; Virginia M Miller
Journal:  Am J Obstet Gynecol       Date:  2017-03-18       Impact factor: 8.661

Review 4.  Preeclampsia and Vascular Function: A Window to Future Cardiovascular Disease Risk.

Authors:  Davaasambuu Enkhmaa; Danielle Wall; Puja K Mehta; Jennifer J Stuart; Janet Wilson Rich-Edwards; C Noel Bairey Merz; Chrisandra Shufelt
Journal:  J Womens Health (Larchmt)       Date:  2016-01-18       Impact factor: 2.681

5.  Long-term mortality risk and life expectancy following recurrent hypertensive disease of pregnancy.

Authors:  Lauren H Theilen; Huong Meeks; Alison Fraser; M Sean Esplin; Ken R Smith; Michael W Varner
Journal:  Am J Obstet Gynecol       Date:  2018-04-07       Impact factor: 8.661

6.  History of Adverse Pregnancy Outcomes, Blood Pressure, and Subclinical Vascular Measures in Late Midlife: SWAN (Study of Women's Health Across the Nation).

Authors:  Yamnia I Cortés; Janet M Catov; Maria Brooks; Siobán D Harlow; Carmen R Isasi; Elizabeth A Jackson; Karen A Matthews; Rebecca C Thurston; Emma Barinas-Mitchell
Journal:  J Am Heart Assoc       Date:  2017-12-29       Impact factor: 5.501

Review 7.  Maternal Venous Hemodynamic Dysfunction in Proteinuric Gestational Hypertension: Evidence and Implications.

Authors:  Wilfried Gyselaers
Journal:  J Clin Med       Date:  2019-03-11       Impact factor: 4.241

Review 8.  Pre-eclampsia is associated with a twofold increase in diabetes: a systematic review and meta-analysis.

Authors:  Pensee Wu; Chun Shing Kwok; Randula Haththotuwa; Rafail A Kotronias; Aswin Babu; Anthony A Fryer; Phyo K Myint; Carolyn A Chew-Graham; Mamas A Mamas
Journal:  Diabetologia       Date:  2016-09-19       Impact factor: 10.122

9.  Oxidative stress and endothelial function in normal pregnancy versus pre-eclampsia, a combined longitudinal and case control study.

Authors:  Dominique Mannaerts; Ellen Faes; Jan Gielis; Emeline Van Craenenbroeck; Paul Cos; Marc Spaanderman; Wilfried Gyselaers; Jerome Cornette; Yves Jacquemyn
Journal:  BMC Pregnancy Childbirth       Date:  2018-02-27       Impact factor: 3.007

Review 10.  Preventing cardiovascular disease after hypertensive disorders of pregnancy: Searching for the how and when.

Authors:  T Katrien J Groenhof; Bas B van Rijn; Arie Franx; Jeanine E Roeters van Lennep; Michiel L Bots; A Titia Lely
Journal:  Eur J Prev Cardiol       Date:  2017-09-12       Impact factor: 7.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.